Viewing Study NCT07290166


Ignite Creation Date: 2025-12-24 @ 4:24 PM
Ignite Modification Date: 2026-01-28 @ 6:51 AM
Study NCT ID: NCT07290166
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-18
First Post: 2025-12-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.
Sponsor: Fudan University
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ER positive and HER2 positive View
None triple-targeted anti-HER2 strategy View
None chemotherapy-free View
None neoadjuvant View